IncFact
Company Profiles: Revenue, Growth, Competition

In-Vitro Diagnostic Substance Manufacturing Industry

NAICS: 325413

For additional companies see the Pharmaceutical & Medicine Manufacturing Industry

Contents

.In-Vitro Diagnostic Substance Manufacturing Market Share: Largest Companies in the In-Vitro Diagnostic Substance Manufacturing Industry

Company HeadquartersRevenue ($ MM)
AALTO SCIENTIFICEatonton, GA100 
SDIXNewark, DE63 
RAYBIOTECHNorcross, GA53 
ZEPTO LIFE TECHNOLOGYSaint Paul, MN39 
LEE BIOSOLUTIONSMaryland Heights, MO37 
CALBIOTECH VETERINARY DIAGNOSTICSEl Cajon, CA37 
ARLINGTON SCIENTIFICSpringville, UT32 
BIOPOOL USJamestown, NY29 
DIAMEDIXMiami Lakes, FL26 
AVIOQResearch Triangle Park, NC26 
QUANSYS BIOSCIENCESLogan, UT26 
RASILIENT SYSTEMSSanta Clara, CA20 


See exact company revenues in this list


This is a list of the largest companies active in the In-Vitro Diagnostic Substance Manufacturing industry. This differs from market share in the following example: One business with revenues of $100 million generates 10% of its business from the In-Vitro Diagnostic Substance Manufacturing industry. A second firm, with revenues of $20 million, generates all of its business from this industry. In our list, we show the businesses having revenues of $100 million and $20 million, respectively. However, the market share would compare the $10 million in industry-specific revenue to the $20 million: the second company has twice the market share even though it is "smaller" in size.


.Additional Companies Operating in the In-Vitro Diagnostic Substance Manufacturing Industry

Company HeadquartersRevenue ($ MM)
ABBOTT LABORATORIES (NYSE: ABT)Abbott Park, IL100 
BECKMAN COULTERBrea, CA15 
IMMUCORNorcross, GA4 
ORTHO-CLINICAL DIAGNOSTICSRaritan, NJ3 
GEN-PROBESan Diego, CA3 
BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANAShreveport, LA2 
CAYMAN CHEMICALAnn Arbor, MI2 
DIASORINStillwater, MN2 




.Growth: Fastest Growing In-Vitro Diagnostic Substance Manufacturing Companies

A list of competitors in the In-Vitro Diagnostic Substance Manufacturing industry that are rapidly expanding. Businesses may grow organically or through acquisition. Typically, small or midsized companies are in "growth" mode and can expand more rapidly. However, large businesses may have the strategy and financial capabilities to scale rapidly. Businesses that employ a "roll-up" strategy make multiple acquisitions of smaller businesses to form a single large corporation that controls a greater market share than its competitors and benefits from economies of scale.

View List


View Full List


.Small Business Financing

Small businesses that have received financing may expand soon. Financing may be required for capital-intensive investments, such as real estate or equipment purchases. In-Vitro Diagnostic Substance Manufacturing businesses may use the financing to cover startup expenses or the costs of hiring new employees. Loans differ from equity investments in the level of risk that is expected: loans frequently have collateral either directly or implicitly through the business or the owners that ensure repayment. Equity investment has the possibility for much greater returns, but offers no guarantee the principle will be repaid. Convertible securities combine the two concepts, but is used by private-equity firms rather than main street startups.

View List


. Venture Funding

These In-Vitro Diagnostic Substance Manufacturing companies are actively raising capital from venture capital firms, private equity, or other investors. Businesses with venture funding generally have higher growth prospects, either through bringing new concepts to market, using innovative business practices, or savvy management.

View List